Remove Blog Remove Fragment Screening Remove Vaccine
article thumbnail

Tom Lehrer's guide to design of SARS-CoV-3 main protease inhibitors for treatment of COVID-32

Molecular Design

> It’s been ages since my last COVID-19 post (How not to repurpose a 'drug') and I’ll kick blogging off for 2021 with a follow up to an even older post (SARS-CoV-2 main protease. Crowdsourcing, peptidomimetics and fragments).

article thumbnail

SARS-CoV-2 Protease Inhibitors: An Attractive Approach for Treating COVID-19

PerkinElmer

1 Although effective COVID-19 vaccines have been developed, variants of SARS-CoV-2 have already emerged for which vaccines are less effective, and many people remain unvaccinated due to certain medical conditions, personal choice, or global access challenges. Journal of the American Chemical Society. 2022;144(7):2905-2920.